Recent developments infectious in the treatment diseases by Nagarajan, K.
. I 
Recent Developmel1ts 
Infectious 
In the Treatment 
Diseases* 
of 
K. NAGARAJAN 
It & D Centre, Searle (India) Ltd., Thane--400 601. 
INTRODUCTION: 
The dev.eJ.oping countr'i:es have been facing 
major health hazards due to the prevalence of 
infectious diseases of various kinds. Poor stand-
ards of living and poon~r standards of sanitation 
and personal and community hygiene have con-
tributed in no small measure to the morbidity 
and mortality induced by such diseases with 
their attendant economic toll. The World 
Health Organization has identified 6 major tro-
pical diseases (1) based upon their enden:licity, 
lethality and inadequate avaiLability of proper 
treatment. These are: Filariasis, Leishmanias-
is, Leprosy, . Mal'aria, Schistosomiasis and Try-
panosomiasis. The first four diseases are pre-
valent in the country and will be taken up for 
discussion in this article. In addition, other 
d·iseases like helminthiasis, amoebiasis and' in-
1ections due to bacteria, tuberculosis, fungi and 
viruses which also afflict the country's popula-
tion to a large ext~'1t will be discussed. It 
must be mentioned at the outset that giant strides 
have been taken in the last decades in control-
ling if not conquering them. This has been 
possible due to several developments in the ap-
proaches to the design of drugs based upon (i) 
understanding the biochemistry of the organisms 
and disease pathology at the cellular, molecular 
and gene level; (ii) use of quantiative structure-
activity relationships and molecular modelling; 
(iii) isolation of body's own defence mechanisms 
and their· production by genetic engineering;, (iv) 
elaboration of immunodiagnostics and vaccines 
by monoclonal antibody and recombinant DNA 
techniques; and (v) newer drug delivery systems. 
MALARIA : 
Malaria is endemic in more than 100 coun-
tries in Africa, Asia and Central and S'outh 
America and in its socio economic impact is the 
most important of the transmissible parasitic 
diseases (2). It is estimated that over 90 mil-
lion cases occur each year throughout the world 
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with India accounting for a substantial per·cent-
age. Conunon forms of malaria are due to Plas-
modium fadiparurn, P.vivax, P.ovale and P.ma-
lariae, all having mosquito as the vector. Hopes 
of eradicating or controlling malaria by use of. 
insecticidal sprays have been abandone<i due to 
mosquitos developing resistance, Biological con-
trols using antUarval parasites such as Bacillus 
thuringiensis H 14 and B. sphaericus or latvi-
vorous fish such as Gambusia and destruction of 
mosquito breeding sites by land drainage schem-
es have limited potentiaL 
4-Aminoquinolines (chloroquine and amO-
diaquine) and the related amino alcohol, quinine 
have good blood schizonto cid all properties, des-
troying the asexual blood forms but are not ac-
tive against the intrahepatic forms. The par-
asites have alrea%iY -become resistant to the first 
two,and omino'us signs portend that the third 
may also succumb. The same has been the 
iiate of the antimetabolite synergistic combin:a~ 
tion, F,ansidar of pyrimethamine 1 and sulpha-
doxine 2. (d1}'~Mefl0quine 3, a quinolyl alcohol 
is a good blood schiz9ntozide for 'v,rhich resist-
ance has been as yet unrepOrted and is adminis-
tered in comhination with 1 and 2, but only in 
emergencies With a high previalence of multi-
drug resistance. 3 exerts its adion by inhibition 
of parasitic RNA and DNA synthesis. A phe-
nanthryl methanol, halofantrine 4, with blood 
schizontocidal activity has been recently approv-
ed fOir the treatment of multidrug resistant ma-
laria. 
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Artemisinin 5 (Qinghaosu), an unusual tri-
oxane, occuring in a traditional Chinese herb, CHJ 
and its dihydro derivative 6 are also blood schi-
zontozides, with a novel mechanism of action. 
The drugs affect the parasite plasma membrane 
first and then the nucleus. This is not the result 
of percixida,tion of lipids. The primary mode of 
action may be inhibition of parasite protein syn-
thesis. For galenical purposes, ethers of 6 such 
as 7 (3) or sodium artesunate 8 (4) are being de-
veloped clinically. These are expected to have 
imporia/nt potential in the treatment of severe 
and complicated malaria. 
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'. Ahtimetaboliteslike proguanil, chlorporo-
guanil arid cydoguanil as well as thetetracy-
clines are active against both the erythrocitic 
and -intra hepatic forms of P.falciparum, but not 
against other rl1alarial parasites whereas prima-'-
quine isactiveagrunst the intra hepatic forms 
of the latter parasites. 
Chemoprophylaxis against malaria is unsa-
tisfactory and depends upon chloroquine, progu-
anil, chlorproguanil, meftoquine and doxycyline. 
Vigorous efforts are being deployed to deve-
lop inununodiagnostics and vaocines for malaria 
but no outstanding successes have been reported. 
FILARIASIS: 
This infestation comprises several diseases, 
mostly caused by filarial worms and transmitted 
by bloodsucking flies. (1) Lymphatic filariasis 
. affects about 90 million people in Asia, Africa 
and South America and additionally 905 million 
are directly exposed to the risk of infection. The 
disease group is caused by the parasites Wucher-
eria bancrofti and Brugia mala'yi and causes 
f d considerable disability and disfigurement an 
chronic lesions like elephantiasis and hydrocoele. 
Onchocerciasis or river blindness caused by On-
chocerca volvulus is more deadly. It affects 40 
million' people mainly in tropical Africa but al-
so in Central and South America and causes se-
vere itching leading ultimately to blindness. 
Lymphatic fil.ariasis can be relatively saf,e-
ly and effectively treated with diethyl carbama-
zine (DEC). _ The drug is mainly microfilar'icid-
acl but in large doses also kills adult worms. Am-
oscanate,9, an aryl-isothio~yanate is an indige-
nously developed drug, with good activity again-
st macrofilaria in experimental animals (5), but 
is not tolerated well by humans. Two benzothia-
zole isothiocy,anate derivatives, 10, (CGI 16343, 
developed in India) and 11 (CGP 20376) have 
good filaricida:l properties and are currently in 
clinical trials in India. 
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-Treatment of onchocerciasis is less satisfac-
tory. DEC kins the microfilaria of the p~rasite 
involved but causes intense undesirable side re-
actions. Suramin, a naphthalene sulphoriiC acid 
derivative, kills the adult worms but is exceed-
ingly toxic. However, ivermectin 12, a semisyn-
thetic ionophofe antibiotic of avermectin family 
has been a breakthrough in the treatment of 
onchocerciasis. This antibiotic is also a wonder 
drug for the treatment of exo and endo parasites 
in sheep, cattle and horses and exerts its acti-
vity in microgr,ams. Interestingly, the manufac-
turers have offered the drug free to the African 
patients. A derivative, CGI 6140 13, of amos-
canate 9 has promisingfil'aricidal activity and is 
underg.oing clinica1 trials in Africa. Benzimida-
zole carbamates like mebendazole (vide infra) 
and flubendazole have parenteral activity against 
lymphatic filariasis and onchocerciasis. 
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Attempts to have immuodiagno&tics and 
prophylactic va.ecines for filariasis have not yet 
resulted in commercial products. 
LEISHMANIASIS: 
These are diseases caused by infection with 
the fi;agellatte protozoan parasite Leishmania 
donovani transmitted by the vector, sandfiy. The 
diseases occur in three forms ~ the mucocut.a-
neous form found mainly in South America, 
while the visceral and cut.aneo~ forms are pre-
valent in the Indian subcontirlent and several 
parts of Africa and Si::>uth America. In visceral 
leishmaniasis, the pamsite mounts an inv~ion 
of internal organs such as spleen and liver; the 
resulting kala-azar is leth'a1. Earlier spraying of 
DDT to control the malarial vector, mosquito, 
suppressed the propagation of sand flies, result-
ing in the checking of leishmaniasis. However, 
this effect wore out in course of time resulting 
in the recrudescenc of the disease in India. Thus 
in 1977, in Bihar over 100,000 people were af-
fected. Unfortunately, there are no proper 
drugs to treat leishmaniasis; pentavalent anti-
monials like urea stibamine and stiboglucamine 
as well as bis-,arnidines like pe~tamidine involve 
painful parenteral application and cause severe 
toxic Slide effects (1). Pyrazolopyrimidine nucle-
osides like allopurinol are cUJTE111tly useful leads 
for developing the much needed newer drugs for 
this indication. 
LEPROSY: 
About 1.4 billion people or nearly a third 
of the world's population live in leprosy-ende-
mic areas mostly in Aflfica and Asia, the figure 
10.6 million rcp~'esenting the number of leprosy 
patients. India harbours a large percentage of 
this population. About a third face the thre{l.t of 
permanent, progressive physical debility often 
with the attendant threat of social rejection. (1). 
The more well-known drugs for the treat-
ment of leprosy are dapsone 14, clofazirnine 15 
and rifampicin 16. 14 is a folate antagonist, 
the activity of 15 has been related to the p-qu~ 
iononirnine system. Rifampicin 16 inhibits DNA 
directed RNA polymerase resul~ing in the inhi-
bit.ion of ItNA. Earlier monotherapy demonstra-
ted rapid development of resistance of the cau-
sative bacterium, Mycobacterium leprae to 
14, less with 16, but rarely with 15. Currently 
used multitherapy seems to give satisfactory 
results. Trials of antibacterial quinolones (vide 
infra) in the mouse f.oot pad test show that at 
least one quinolone derivative is active against 
M. leprae. Some ~-la.ctam antibiotics and am-
inologycosides are also active. 
M. leprae specific monoclonal antibodies are 
now available and are being used to deveLop irn-
munodiagnostics for leprosy. A few vaccines 
are also under clinical trials. (1). 
GASTRO-INTESTINAL HELMINTHS: 
Some of the common parasites that infest 
men are tapeworms, roundworms, bookworms, 
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pin worms and whipwor.ms.Over 1 billion of the 
wodd's population is estimated to harbour ro-
undworms; the book worms are more deadly in 
that theyc.olonise the intestinal wall and suck 
blood continuously. The total daily blood con-
sumption of these worms which parasitize at 
least 800 million humans is equivalent 1:;0 the 
total exsanguination of 2 million people! (6). 
For the trea,tment of tapeworm infectioll.S 
apart £i'om niclosamide, a chlorosalicylanilide 
derivative, must. be mentioned, a new·er drug 
praziquantel 17 which is effective at a singl,e 
dose. 17, is more known for its activity against 
all the three forms of schistosomiasis, viz. S. 
IT.'ansoni, S. haematobium and S. japanicum. 
Schistosomiasis is one of the 6 major tropical 
diseases and afflicts Africans and South Americans 
but is not endemic tOffi'India. Amoscanate 9is also 
active against the three species while ox amini-
quine 18, a nitroquinoline derivative is a schis,-
tosomicide but only for infections' due to S. 
mansoni. 
o:=.c-Q . '. 
1 ' 
',< 
The benzimidazole, thiabendazole 19, rep-
resented the first truly broad-spectrum intestinal 
nematodicide, useful for the eradication of most 
intestinal nematodes with the possible exception 
of the whipworms. It appears to inhibit the fu-
marate reductase system of susceptible parasi-
tes. Benzimidazole-2-carbamates, represented 
by mebendazole 20, are clear improvements over 
19 and offer really effective treatment. The me-
chanism of action of 20 may be related to its 
parasitetubulin binding properties. Albendazole 
(21) and fenbendazole (22) are other popular car-
bamates, while the thiazolyl analogue, CGI 
13866 (23) is a drug of indigenous development 
in clinical trials. B,enzimidazole-2-carbamate it-
self is a plant antifungal agent. 
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Other modern drugs with broad spectrum 
anthelmintic a'ctivity are the thienyl vinyl py_ 
rimidine, pyrantel 24 and the imidazothiazole, 
tetramisole 25 in the racemic form; (the laevo 
rot,ary isomer, laevamisole is also active). The 
former is a parasite-neuromuscular depolariz-
ing agent, while the latter is a fumarate reduc~ 
tase inhibitor. Incidentally, 25 has antidepress-
ant, antiinflammatory and nonspecific immuno-
stimulatory properties also! Amoscanate 9 was 
also developed and registered as an anthelmin-
tic agent in India (5,7). 
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AMOEBIASIS: 
Amoebiasis, a protozoal infection caused by 
Entamoeba histolytica is said to affect 10% of 
the world population with a }j)igh prevalence 
late in the tropics upto 100.%. The main sites of 
infection are the intestine and to a lesser ex-
tent, the liver. (8) Current drugs of choice be-
long to the metronidazqle grol!lp (9) represented 
by the weUknown metronidazole 26 and the sul-
phtme, tinidazole 27 which are available in In-
dia. Satr'anida:wle 28, developed Locally and re-
gistered in India is a more potent amoebis:ide 
(10) but is unlikely to be marketed. The 111troi-
l11jda:wles are particularly us'eful for the treat-
ment oJ hepatic amoebiasis, but they have a 
wide spectrum of antimicrobial properties 
activity against trichomonas, giardia, anaerobic 
bacteria, etc. etc. Satranidazole 28 is more po-
tent than 26, in many of these indi.cations esp. 
against anaerobes. (11) Metronidazole is selecti-
vely toxic to anaerobes and protozoa because it 
can accept ele.ctrons at the level of pyruvate 
metabolism at potentials which are incapable of 
being generated in aerobic cells. A transient ni-
tro radical anion is formed which damages the 
parasite DNA by helix destabilization and strand 
breakage, (8) 
28. 
~
Dichloroacetanilides like di10xanide furoate 
29 are particularly effective against lumen-
dwelling amoeba, Juinfamide 30 is reported to 
be more potent (8). Inhibition of protein synthe-
sis in the parasite by 29 may be the cause for 
its lethality. (8) 
(R= 2-Furoyt ) 
TUBERCULOSIS: 
Rifampicin 16 has without doubt revolu-
tionised the theapy of tuberculosis, .helping in 
avoiding hospitalisation and promoting ambula-
t?ry treatment. As in the case of leprosy, mul-
tJ.ple therapy is necessary to avoid develop-
ment of resistance. A recommended combination 
is of 16 with isoniazide and ethambutol. Strep-
tomycin, thiacetazone, thionamide and pyrazina-
mide are also in use (12). Uniquely among ni-
troimidazoles, the imidazooxazole derivative 31 
has in vivo antitubercuLar activity in mouse ex-
periments. (13) 
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The quinolone antibacterials. 
cin (vide infra) have cLinically 
antitubercular ·acitvity. 
BACTERIAL ~NFECTIONS: 
esp. norfioxa-
demonstrated 
Not being confined to tropical oountries this 
area continues to see important d2velop~ents. 
The sulpha synergistic combination cotrimoxa-
zole of trimethoprim 32 and sulphamethoxazole 
33 is still very populiar in India. Cotrimoxazole 
exerts its antibacterial action by sequential bloc-
kade of bacterial folate synthesis. . . 
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Ampicillin 34 and cephalexin 35 are repre-
sentative examples of the penicillin and cepha-
losporin group respectively. Their activity is re-
lated to inhibition of bacterial cell wall biosyn-
thesis. Rapid deactivation by the enzyme, beta-
lactamase has been a persistent problem in this 
field. Inhibitors like clavulanic acid 37 and sul-
bactam are valuable discoveries in this respect. 
A combination, augmentin comprising amoxi-
cillin 36 and 37 has been a major breakth-
rough; timentin is a similar combination of 37 
with ticaricillin. (14) Current efforts in this field 
are devoted to dis1covery of cephalosporin anti-
biotics which are orally active and have' along 
half-life and broad spectrum, such as cefixime, 
cefetram pivoxil and cefpodoxime. The introduc-
tion of a formamido or methoxy group at posi-
tion 7 on the cephalosporin framework. imparts 
~-llactamase resistance to the drug. 
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Thienamycin 38, a carbapenem has an ex-
traordinarilybroad spectrum of antibacterial 
activity, including recalcitrant bacteria like 
Pseudomonas aeruginasa and anaerobes but is 
be~t with solubility problems. Several other 
carbapenems and carbacepheJ'!ITs are under study. 
Aztreonam 39, belonging to the monobactam 
group is remarkable for its imperiviollsness 'to 
beta-lactamase. (15) However, its activity is ma-
:nlY only against gram negative bacteria. No,.. 
('ardicin and tigemonam are other members of 
this group. The former is active against P. aeru-
ginosa, Proteus species and Neisseria. In ,~itro it 
is not active against E. coli, but is so in vivo. Al-
Vancomycin 40 is a gJycopeptide antibiotic 
with marked activity against gram positive bac-
tETia. Its combination with gentamycin or strep-
ptomycin is synergistic. Its use is reserved for 
life-threatening situations against resistant bac-
teria, 40 is also reported to have antituberculm 
activity, TeicoplJanin is another such glycopep-
tide antibiotic with a longer. half life than van-
comycin, (16) Daptamycin is the first reported 
antibacterial lipopeptide. 
. hough it interferes with cell-WJall synthesis, the 
mechanism is said to be different from that of 
penicillin. 
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The ftuoroquinolone antibacterials (17) re-
p:'esent the roost recent and major milestone in 
antibacterial chemotherapy, having their origin 
in nalidixic acid. Norft.oxacin 41, ciproft.oxacin 
42 and peftoxacin 43 are some typical members, 
while ofloxacin is a tricyclic analogue. They 
have a wide range of activity - all bacterial 
pathogens of urogenital tract infections, diarrho-
eal diseases, gonorrhoea, ophthalmological in-
fections, etc. They are highly active aga·inst pseu-
domonas. Their activity in leprosy and tuber-
culosis has been noted eaalier. They have a good 
oral absorption .and a long half-life. They are 
free from the risk of emergence of resistance at-
least for the moment. Finally their mode of ac-
tion is nove} - potent and specific blocking of 
bacterial. DNA gyra_se leading to inhibition of 
synthesis as well as functions of DNA resulting 
in rapid bacteriolysis. Norftoxacin is already av-
ailable in the country. 
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constituent of the. lipopolysaccharide of the ou-
ter membrane of gram-negative bacteria. Rela-
ted; coni.pOlmdsof the type 47 where R = L-
alanyl-NH etc inhibit the enzyme involved and 
provide a different appro.ach for antibacterial 
chemotherapy. (19) Bicydic pyrazolidinones of 
general structure 48 (?) have been reported to 
have potent in vivo antibacterial activity. (20) 
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Finally in this section may be noted new 
le.<iGjS. OXjazolidinones, DuP 721 44 and DuP 105 
45 have, wide spectrum activity against gram po-
::;::.tive and negative bacteria and are highly po-
'cnt in 'animal experiments. Activity is exerted 
by inhibition of protein biosynthesis before ini-
tiation of peptide chain formation (18). 3-Deoxy- '8 
p,-m:anno-2-:odulos:onic acid 46 (,8 -KDO) is a. ~ -..... 
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FUNGAL iNFECTIONS: 
The 'widespread use of , immuosuppressants 
for thec0ntml of cancer alJld in other situations 
(e.g 01;gan~transplants) has given rise to an up~ 
sunge of opportunistic infections like those ,due 
to fungi which particularly in the \Vest has as-
snmedalarming, sometime lif:e~thraatening,pr.o­
portions (21).,hnidazoles mark the beginniI1gs ,of 
modern an.,tiiungal therapy. 'Dhe prototype clo-
trimazole 49, is used topicarly for infections due 
to the common fungus, Candida albicans; , this 
was followed by miconozole50. Systematic ac-
tivity is obtained in more complicated molecules 
like keticonazole 51. The activity extends to tri-
azole derivatives like itraconazole and flucona-
zole and fluconazole as welL 'Antifungal aotivity 
in this class of drugs is elicited primarily through 
inhibition of steroidogenesis. The newer triazoles 
offer greater selectivity and affect mrunmalian 
enzymes less. 
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Vacciria t ion against the small pox virus hac; 
en successful. in total global eradication Gene-
tically eng.ineered vaccines using l..,DNA techno-
logy are available for hepatitis. Vaccination ag-: 
ainst the influenza virus has not been very suc-
cessful. Synthetic compounds like amantadine 
52 and rimantadine 53 have limited applications. 
N ucleosides like vidarabine 54 and ribavirin 55 
are somewhat successful in treating influenza A 
and B and other RNA, DNA viral infections, 
while acydovir 56 represents the currently av-
ailable drug for the treatment of painful infec-
tions due to genital herpes. Retrovir (AZT) 57 
a pyrimidine nucleoside has become well-kn-
own as the only drug approved at the moment 
for treating the AIDS causing infection due to 
the retrovirus HIV. (22) 57 is known to be only 
a palliative. 
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--Azathioprine 58, a purine derivative, is 
used as an immunosuppressant in patients with 
kidney transplants. The life-saving drug has be-
comeav.aila,ble in India throvgh a proci::ss deve-
loped in :our laboratories. The cyclic poh;;pep-
tide, cyclosporin 54 also has immunosuppressive 
properties. (23) It was originally isolated in Eu-
;~ope from the fungus Tolypocladium infiatum. 
An Indian source, Tolypocladium cylindrospo-
rum has been announced. (24) 
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